Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Gold IRA Companies
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Gold IRA Review
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ARQT
Stock Latest News
Company Announcements
Arcutis Earnings Call Signals Momentum Amid Headwinds
25d ago
ARQT
Premium
The Fly
Arcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley
28d ago
ARQT
Premium
Ratings
Arcutis Biotherapeutics: Buy Rating Reaffirmed as Zoryve Momentum Supports Growth Outlook; $35 Price Target Maintained
28d ago
ARQT
Premium
Ratings
Analyst Reiterates Buy on Arcutis as Zoryve Momentum, New Data Support Unchanged $34 Price Target
28d ago
ARQT
Premium
Ratings
Arcutis Biotherapeutics Reaffirmed at Buy as Growth Outlook Strengthens; $36 Price Target Maintained
29d ago
ARQT
Premium
The Fly
Arcutis Biotherapeutics reports Q1 EPS (9c), consensus (6c)
29d ago
ARQT
Premium
The Fly
Arcutis Biotherapeutics backs FY26 revenue view $480M-$495M, consensus $498.07M
29d ago
ARQT
Premium
The Fly
Arcutis Biotherapeutics submits Zoryve supplemental new drug application
1M ago
ARQT
Premium
Ratings
Arcutis Biotherapeutics: Near-Term Cost Pressures but Intact Long-Term Growth Thesis Supports Buy Rating
1M ago
ARQT
Premium
The Fly
Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream
2M ago
ARQT
Premium
The Fly
Arcutis Biotherapeutics to present clinical data on ZORYVE at AAD Meeting
3M ago
ARQT
Premium
The Fly
Arcutis Biotherapeutics announces publication on Phase 3 study of Zoryve cream
3M ago
ARQT
Premium
Company Announcements
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
3M ago
ARQT
Premium
The Fly
Arcutis announces promotion of Matsuda to EVP, Chief Legal Officer
3M ago
ARQT
Premium
Company Announcements
Arcutis (ARQT) Earnings Call Signals Scaled Growth
3M ago
ARQT
Premium
The Fly
Arcutis first participant enrolled in Phase 1a/1b trial of ARQ-234-131
3M ago
ARQT
Premium
The Fly
Arcutis Biotherapeutics price target lowered to $35 from $37 at Mizuho
3M ago
ARQT
Premium
The Fly
Arcutis Biotherapeutics price target raised to $35 from $34 at Guggenheim
3M ago
ARQT
Premium
The Fly
Arcutis Biotherapeutics price target raised to $35 from $30 at TD Cowen
3M ago
ARQT
Premium
The Fly
Arcutis Biotherapeutics price target raised to $35 from $32 at Morgan Stanley
3M ago
ARQT
Premium
Ratings
Arcutis Therapeutics: Commercial Outperformance and Upgraded Zoryve Outlook Support Buy Rating
3M ago
ARQT
Premium
Ratings
Arcutis Biotherapeutics: Zoryve’s Outperformance and Strengthening Outlook Support Buy Rating and Higher $36 Target
3M ago
ARQT
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
